Eleftheria Tsakalozou

Eleftheria Tsakalozou

Auto-generated profile, based on publicly available information

Eleftheria Tsakalozou

Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research U.S. Food and Drug Administration Silver Spring Maryland USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2022 in CPT: Pharmacometrics & Systems Pharmacology
Verified
Journal Article
Open access
ETEleftheria Tsakalozou
Eleftheria Tsakalozou
KAKhondoker Alam
Khondoker Alam
PGPriyanka Ghosh
Priyanka Ghosh
JSJessica Spires
Jessica Spires
SPSebastian Polak
Sebastian Polak
SRSam G. Raney
Sam G. Raney
The development of a generic drug product involves demonstrating that there is no significant difference in the rate and extent to which the active ingredient becomes available at the site of action, relative to the reference listed drug product. This remains challenging for many locally acting topical dermatological products because measuring the concentration of the active ingredient at the site of action in the skin may not be straightforward, and, in most instances, there are no established relationships between skin and plasma pharmacokinetic profiles. In recent years, the Office of Generic Drugs of the US Food and Drug Administration (FDA) established scientific research programs with the goal of enhancing patient access to high quality, affordable topical dermatological generics. A key strategy of these research programs was to leverage modeling and simulation methodologies that accelerate the development of these generics by facilitating alternative bioequivalence approaches for dermatological drug products. This report summarizes relevant insights and discussions from a 2021 FDA public workshop titled “Regulatory Utility of Mechanistic Modeling to Support Alternative Bioequivalence Approaches,” which illustrated how mechanistic modeling and simulation approaches can be utilized (and have been used) to inform generic drug product development and regulatory decisions during the assessment of generic drug applications submitted to the FDA.

24 October 2025 in The AAPS Journal
Verified
Journal Article
Open access
PDF file
Daniela Amaral SilvaDaniela Amaral Silva
Daniela Amaral Silva
MMMaxime Le Merdy
Maxime Le Merdy
JMJames Mullin
James Mullin
NMNilesh Malavia
Nilesh Malavia
KAKhondoker Alam
Khondoker Alam
VLViera Lukacova
Viera Lukacova
The tissue response to long-acting injectables (LAIs) suspension injection may impact the product in vivo performance. One such response is the formation of an inflammatory cell layer (ICL) resulting in an envelope around the injected particles. This study aims to use a mechanistic model to describe the clinical in vivo exposure and performance of an intramuscular LAI suspension and evaluate impact of ICL physiological response at the injection site in humans. Aripiprazole lauroxil (AR-L) was used as the model drug. A baseline pharmacokinetics model was built and validated for aripiprazole. The impact of inflammation on the LAI in vivo performance was assessed by including an ICL model. The developed pharmacokinetic model adequately described the observed plasma profiles of AR following intravenous and oral administration in humans. The initial intramuscular predictions assumed that the absorption rate is dependent on the dissolution and partitioning of AR-L into the systemic circulation from the intramuscular (IM) depot. The simulation resulted in a shape mismatch between the simulated and observed data and an earlier predicted T max. The inclusion of an ICL in the model resulted in adequate predictions (fold errors less than 25%) of the exposure and shape of the plasma concentration–time profiles. Utilizing a time-dependent change in ICL thickness resulted in reasonable predictions of AR pharmacokinetic profiles following IM administration of multiple strengths of the AR-L suspension. This shows the utility of physiologically based pharmacokinetic (PBPK) model in mechanistically describing the in vivo performance of LAIs. Graphical Abstract

2 October 2023 in The AAPS Journal
Verified
Journal Article
Closed access
PDF file
ETEleftheria Tsakalozou
Eleftheria Tsakalozou
MMMohamed-Eslam F. Mohamed
Mohamed-Eslam F. Mohamed
SPSebastian Polak
Sebastian Polak
THTycho Heimbach
Tycho Heimbach

17 July 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
PDPankaj Dwivedi
Pankaj Dwivedi
PKPriyata Kalra
Priyata Kalra
HZHaiying Zhou
Haiying Zhou
KAKhondoker Alam
Khondoker Alam
ETEleftheria Tsakalozou
Eleftheria Tsakalozou
GPGiovanni M. Pauletti
Giovanni M. Pauletti
Background/Objectives: The oral cavity represents a convenient route of administration for drugs that exhibit significant hepatic first-pass extraction. In this study, the mucosal permeation properties of selected active pharmaceutical ingredients (APIs) incorporated into oral cavity drug products that are approved by the U.S. Food and Drug Administration were quantified using the human-derived sublingual HO-1-u-1 and buccal EpiOral™ in vitro tissue models. Methods: Epithelial barrier properties were monitored using propranolol and Lucifer Yellow as prototypic transcellular and paracellular markers. APIs were dissolved in artificial saliva, pH 6.7, and transepithelial flux from the apical to the basolateral compartment was quantified using HPLC. Results: Apparent permeability coefficients (Papp) calculated for these APIs in the sublingual HO-1-u-1 tissue model varied from Papp = 2.72 ± 0.06 × 10−5 cm/s for asenapine to Papp = 6.21 ± 2.60 × 10−5 cm/s for naloxone. In contrast, the buccal EpiOral™ tissue model demonstrated greater discrimination power in terms of permeation properties for the same APIs, with values ranging from Papp = 3.31 ± 0.83 × 10−7 cm/s for acyclovir to Papp = 2.56 ± 0.68 × 10−5 cm/s for sufentanil. The tissue-associated dose fraction recovered at the end of the transport experiment was significantly increased in the buccal EpiOral™ tissue model, reaching up to 8.5% for sufentanil. Conclusions: Experimental permeation data collected for selected APIs in FDA-approved oral cavity products will serve as a training set to aid the development of predictive computational models for improving algorithms that describe drug absorption from the oral cavity. Following a robust in vitro–in vivo correlation analysis, it is expected that such innovative in silico modeling strategies will the accelerate development of generic oral cavity products by facilitating the utility of model-integrated evidence to support decision making in generic drug development and regulatory approval.

10 January 2024 in The AAPS Journal
Verified
Journal Article
Closed access
PDF file
ETEleftheria Tsakalozou
Eleftheria Tsakalozou
LFLanyan Fang
Lanyan Fang
YBYouwei Bi
Youwei Bi
MHMichiel van Den Heuvel
Michiel van Den Heuvel
TATausif Ahmed
Tausif Ahmed
LZLiang Zhao
Liang Zhao

24 September 2025 in CPT: Pharmacometrics & Systems Pharmacology
Verified
Journal Article
Open access
AHAbdullah Hamadeh
Abdullah Hamadeh
MPMoriah Pellowe
Moriah Pellowe
PCPierre Chelle
Pierre Chelle
CYCindy Hoi Ting Yeung
Cindy Hoi Ting Yeung
JOJulian Otalvaro
Julian Otalvaro
AEAndrea Edginton
Andrea Edginton
To establish bioequivalence (BE) of a generic test formulation with respect to a reference listed drug, it is necessary to demonstrate a comparable rate and extent to which active ingredients reach the site of action. To decrease unnecessary human testing and simulate scenarios involving specific populations or challenges with recruitment or study design, industry and regulators are increasingly considering in silico virtual bioequivalence (VBE) approaches. This tutorial introduces the VBEToolbox R package: a toolbox within the Open Systems Pharmacology framework to streamline and standardize computational VBE workflows. The package integrates in vitro and in vivo data to train pharmacokinetic models through inference of inter‐individual variability from clinical data and establishment of in vitro to in vivo extrapolations. A nonparametric approach is adopted to account for uncertainties from parameter non‐identifiability. The trained model is then applied to determine the study size with statistical power needed to demonstrate BE virtually. The use of the VBE tool is illustrated with two case studies. The first evaluates the VBE of petrolatum and ethylene glycol dermal formulations of testosterone by integrating in vitro skin permeation tests, vehicle/skin partitioning data, testosterone solubility data, and in vivo absorption data in a mechanistic in vitro/in vivo dermal absorption model. The second assesses the VBE of two oral bupropion formulations by integrating in vitro dissolution data in a physiologically based pharmacokinetic model. These case studies highlight essential considerations for model development, training, and extrapolation toward application for VBE assessment.